To investigate the contribution of LamB in Klebsiella pneumoniae antimicrobial resistance, we determined the MICs of various antibiotics and the frequency of mutation to increased cefoxitin or meropenem resistance of the strains CSUB10S (expressing only OmpK36), CSUB10R (lacking OmpK35 and OmpK36), and their derived isogenic insertion-duplication mutants deficient in LamB. Expression of LamB was indispensable in order for CSUB10S to lose OmpK36 and become resistant to cefoxitin, while in CSUB10R, LamB deficiency promoted increased resistance to carbapenem.
An increasing emergence of multidrug resistance among Klebsiella pneumoniae nosocomial isolates has limited the therapeutic options for the treatment of the intrahospital infections caused by this opportunistic pathogen. A multidrug resistance phenotype results from the progressive accumulation of different mechanisms of resistance in the same microorganism, including high-level production of extended-spectrum ␤-lactamases (ESBLs) and porin deficiency. K. pneumoniae produces two major porins, OmpK35 (8) and OmpK36 (1) . However, most ESBL-expressing K. pneumoniae clinical isolates produce only OmpK36 (11) . Clinical and experimental evidences indicate that loss of these major porins in K. pneumoniae strains producing ESBLs causes resistance to cefoxitin, increased resistance to expanded-spectrum cephalosporins and monobactams, and decreased susceptibility to fluoroquinolones (8, 9, (12) (13) (14) 15) .
Besides the major porins, K. pneumoniae may express other porins, such as PhoE, OmpK37, and LamB (3, 7, 13) . These alternative porins may be crucial for the microorganism in the absence of OmpK35/36, although their contribution to antimicrobial resistance has been poorly investigated. In a previous study, the outer membrane protein (OMP) profile of the susceptible K. pneumoniae clinical isolate CSUB10S (expressing only OmpK36) and that of its resistant clinical derivative CSUB10R (lacking both OmpK35 and OmpK36) were compared (3). It was observed that LamB may be a predominant OMP in the resistant isolate compared to the susceptible one, suggesting that LamB may contribute to resistance in K. pneumoniae. To verify this result, the amounts of LamB present in the outer membrane of CSUB10S and CSUB10R grown in cation-supplemented Mueller-Hinton broth (MH) or in human pools of urine or serum were analyzed by SDS-PAGE as previously described (11) . As shown in Fig. 1 , the outer membrane of the resistant isolate contained larger amounts of LamB than that of the susceptible one, both in MH and in the physiological fluids. Densitometric analysis of the intensity of the band of LamB normalized for the band of OmpA of three independent gels demonstrated that in MH, CSUB10R produces 1.86-fold Ϯ 0.09-fold more LamB than CSUB10S (P ϭ 0.001, twotailed t test). Furthermore, reverse transcription-PCR (RT-PCR) quantification of the amount of lamB mRNA in both strains showed that CSUB10R expresses 2.17-fold Ϯ 0.6-fold more lamB than CSUB10S (P ϭ 0.04, two-tailed t test).
In order to investigate the role of LamB in K. pneumoniae antimicrobial resistance, we used insertion-duplication mutagenesis to construct LamB-deficient knockouts from both CSUB10S and CSUB10R, following the strategy previously described (16) (Fig. 2A) . Southern blot analysis of the genomic DNA of both knockouts using a specific probe for lamB confirmed that two incomplete copies of the gene were generated by the integration of the plasmid (Fig. 2B ). SDS-PAGE analysis confirmed that the lamB mutation abolished the expression of LamB in both knockouts (Fig. 2C) .
The susceptibilities of the clinical isolates CSUB10S and CSUB10R and their derived isogenic LamB-deficient knockouts, CSUB10S⌬lamB and CSUB10R⌬lamB, to a number of antibiotics were determined using Etest strips (bioMérieux, Marcy l'Etoile, France), following the manufacturer's instructions ( Table 1 ). The absence of LamB in the susceptible isolate CSUB10S did not caused significant changes in the MICs of the agents tested. Only modest reductions in the MICs of ceftazidime, cefepime, cefotaxime, tobramycin, amikacin, and levofloxacin were observed. This was an expected result given that in the presence of OmpK36, the contribution of LamB to the penetration of these antimicrobial agents is probably neg- ligible. In contrast, LamB deficiency in the OmpK36-deficient resistant isolate CSUB10R slightly increased the MICs of cefepime, piperacillin-tazobactam, cefotaxime, imipenem, meropenem, and ertapenem, suggesting that LamB may contribute to the penetration of these agents in the porin-deficient strains.
Cefoxitin resistance in CSUB10R is caused by the loss of both OmpK35 and OmpK36 (14) . In order to study if the overexpression of LamB compensates the loss of these major porins in the resistant isolate, we determined the frequency of mutation to cefoxitin resistance in CUSB10S and CSUB10S⌬lamB. The mutation frequency was examined by determining the proportion of resistant colonies with regard to the total viable cell count as previously described (5) . The frequency of mutation to cefoxitin resistance (32 g/ml) of the parent strain CSUB10S was 10 times higher than that of the LamB-deficient mutant CSUB10S⌬lamB (1.86 ϫ 10 Ϫ8 versus 9.9 ϫ 10 Ϫ9 ; P ϭ 0.048) (Fig. 3A) . SDS-PAGE analysis of the OMPs of some randomly selected cefoxitin-resistant isolates derived from CSUB10S confirmed the absence of OmpK35/OmpK36 (Fig. 3B) . Furthermore, the analysis of the OMPs of some randomly selected cefoxitin-resistant isolates derived from CSUB10S⌬lamB revealed that the LamB-deficient phenotype, which is highly stable, reverted to the wild-type phenotype in the presence of cefoxitin (Fig. 3C ). This suggests that during the development of resistance to cefoxitin by OmpK35/OmpK36 loss, there are strong selective pressures for the expression of LamB. The mean MICs of the antimicrobial agents tested in Table 1 of 10 randomly selected cefoxitin-resistant mutants derived from either CSUB10S or CSUB10S⌬lamB were identical to those reported for CSUB10R in Table 1 .
To investigate if LamB contributes to the penetration of meropenem in CSUB10R, we determined the frequency of mutation to increased meropenem resistance following the protocol described above but using meropenem (2 g/ml) instead of cefoxitin. The LamB-deficient mutant CSUB10R⌬lamB exhibited a higher mutation frequency (1.43 ϫ 10
Ϫ6
) than its parent strain, CSUB10R, for which it was undetectable (Ͻ1.0 ϫ 10
Ϫ11
). SDS-PAGE analysis of the OMPs from the meropenem-resistant isolates derived from CSUB10R⌬lamB confirmed that the LamBdeficient phenotype was conserved but also revealed the presence of a new protein of about 26 kDa (data not shown).
In this study, we have shown that deficiency of the major porin OmpK36 is associated with the overexpression of LamB. Similar results have been reported for organic solvent-tolerant Escherichia coli mutants (2) and for some Enterobacter aero- genes clinical isolates (10) . Despite the fact that this association could be explained in part by coregulation with major porin expression at the level of transcription and/or at the level of translation (4, 6) , the contribution of LamB to antimicrobial resistance had not been studied accurately. Our results using isogenic LamB-deficient mutants demonstrate that overexpression of this porin is an essential mechanism to compensate the loss of the major porin OmpK36 and allows K. pneumoniae to show high levels of resistance to various classes of antibiotics. Furthermore, in the porin-deficient background, LamB deficiency promoted decreased susceptibility to carbapenem. Similar results were obtained by Kaczmarek et al. when they studied PhoE (13) . In their study, PhoE compensated the loss of the major nonspecific porins, and downregulation of phoE was involved in carbapenem resistance.
Interestingly, LamB deficiency was associated with the expression of a 26-kDa protein which might compensate the loss of LamB and contribute to carbapenem resistance. Further investigations, currently in progress, are necessary to know the contribution of this novel protein in the porin-deficient isolates resistant to carbapenem. LamB PORIN AND ANTIMICROBIAL RESISTANCE 1805
